Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor exhibiting antiangiogenic activity.
Sunitinib demonstrated improved outcomes in comparison to interferon-α in a large phase III study of treatment naïve patients with metastatic renal cell carcinoma. Maintaining patients on sunitinib treatment is essential for a sustained disease control as higher exposure to sunitinib has been associated with an improved overall response rate, progression-free survival and overall survival. Various studies have compared the outcomes of patients undergoing sunitinib therapy based on modifications from their standard dose and schedule. Several studies have shown that switching to an alternate schedule with more frequent dose interruptions without affecting dose density over a 6-week cycle is associated with improved outcomes and increased tolerability.
Written by:
Kalra S, Rini BI, Jonasch E. Are you the author?
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston; Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, USA.
Reference: Ann Oncol. 2015 Jan 26. pii: mdv030.
doi: 10.1093/annonc/mdv030
PubMed Abstract
PMID: 25628443